• Biology, Medicine
  • Published in
    Frontiers in bioscience : a…
    2008
  • DOI:10.2741/2847

New cancer therapy using genetically-engineered oncolytic Sendai virus vector.

@article{Kinoh2008NewCT,
  title={New cancer therapy using genetically-engineered oncolytic Sendai virus vector.},
  author={Hiroaki Kinoh and Makoto Inoue},
  journal={Frontiers in bioscience : a journal and virtual library},
  year={2008},
  volume={13},
  pages={
          2327-34
        }
}
We have developed a new type of Sendai virus-(SeV) based gene transfer vectors for cancer therapy. The matrix gene-, indispensable for particle formation, deficient and fusion gene-, essential for cell-fusion and deciding viral tropism, redesigned SeV vector loses vector particle formation from transduced cells and gains cell-to-cell spreading in protease-dependent, namely controllable, manner. For the selective delivery to malignant tumor cells expressing matrix metalloproteinases (MMPs) or… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 10 CITATIONS

Fusogenic Viruses in Oncolytic Immunotherapy

VIEW 1 EXCERPT
CITES BACKGROUND

References

Publications referenced by this paper.
SHOWING 1-10 OF 23 REFERENCES

Recombinant Sendai virus vector induces complete remission of established brain tumors through efficient interleukin-2 gene transfer in vaccinated rats.

Generation of a recombinant Sendai virus that is selectively activated and lyses human tumor cells expressing matrix metalloproteinases

  • T Morodomi, Y Ogata, Y Sasaguri, M Morimatsu, H Nagase
  • Gene Ther
  • 2004

Safety and immunogenicity of intranasal murine parainfluenza virus type 1 ( Sendai virus ) in healthy human adults

  • HO Li, YF Zhu, +9 authors M Hasegawa
  • Vaccine
  • 2004

Protective efficacy of an AIDS vaccine , a single DNA priming followed by a single booster with a recombinant replication - defective Sendai virus vector , in a macaque AIDS model

  • M Kato, H Igarashi, +10 authors T Matano
  • J Virol
  • 2003